Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Find a broker to begin trading GALT now

Company Name Galectin Therapeutics
Market/Symbol NASDAQ: GALT
Recent Price
Market Cap $80.44M
Avg. Daily Vol. (3m) 608,792
Price/Book N/A
Price/Cash Flow N/A
As of May. 23, 2017
*Source: QuoteMedia

Begin trading GALT

 Find Broker

Recent Company Videos

Galectin Therapeutics: Mutliple Near-Term Phase 2 Trials for Fibrosis

Apr. 27, 2015

Galectin Therapeutics (NASDAQ: GALT) - Presentation and Q/A session recorded at the April 2015 RedChip Global Online CEO Conference. Galectin ...

Galectin Therapeutics Latest News

Ask the CEO

Want more information? View our latest virtual conference.

Receive GALT Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market